Literature DB >> 20927570

Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery.

Stella Blasel1, Kea Franz, Hanns Ackermann, Stefan Weidauer, Friedhelm Zanella, Elke Hattingen.   

Abstract

We observed a stripe-like pattern of regional cerebral blood volume (rCBV) increase in a defined region adjacent to the contrast enhancement (CE) on MRI of glioblastomas (GBM) that we defined as the "striate sign" (SS). We hypothesized that the SS marks infiltration of GBM outside the CE volume transforming into future CE tumor in the follow-up. T2*-weighted dynamic susceptibility-weighted CE (DSC)-MRI, and T1 and T2-weighted images (WI) of 16 patients with GBM were retrospectively evaluated in a baseline MRI performed before neurosurgery. In seven of these patients we also performed a (1)H MR spectroscopic imaging ((1)H MRSI). The regions of interest (ROI) delineating the SS were defined on rCBV maps for each patient. ROIs were overlaid on follow-up T1-WI and T2-WI MRI performed 3, 6, and 9 months after neurosurgery. Size and maximum signal intensity (max SI) of de novo CE within the area of the SS were analyzed. Statistical analysis was performed with the Friedman test (P < 0.05). In 15/16 patients de novo CE completely covered the area of the SS within nine months. Normalized max SI of de-novo CE of the 3, 6, and 9-months follow-up MR examinations were significantly higher than in the baseline MRI (P < 0.001). Normalized choline was increased within the SS in all patients with de novo CE (n = 6). De-novo CE appeared within the SS in all patients (96% of all slices). This implies that the SS might indicate the site of future CE tumor, which represents the area of tumor growth after neurosurgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927570     DOI: 10.1007/s11060-010-0421-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

Review 1.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

Review 2.  Clinical applications of intracranial perfusion MR imaging.

Authors:  M H Lev; B R Rosen
Journal:  Neuroimaging Clin N Am       Date:  1999-05       Impact factor: 2.264

3.  Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses.

Authors:  Vivek Sehgal; Zachary Delproposto; Djamel Haddar; E Mark Haacke; Andrew E Sloan; Lucia J Zamorano; Geoffery Barger; Jiani Hu; Yingbiao Xu; Karthik Praveen Prabhakaran; Ilaya R Elangovan; Jaladhar Neelavalli; Jürgen R Reichenbach
Journal:  J Magn Reson Imaging       Date:  2006-07       Impact factor: 4.813

4.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis.

Authors:  L Ostergaard; R M Weisskoff; D A Chesler; C Gyldensted; B R Rosen
Journal:  Magn Reson Med       Date:  1996-11       Impact factor: 4.668

5.  A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.

Authors:  Marc C Chamberlain; Lisa Chalmers
Journal:  J Neurooncol       Date:  2006-10-04       Impact factor: 4.130

6.  Perfusion MRI in the evaluation of the relationship between tumour growth, necrosis and angiogenesis in glioblastomas and grade 1 meningiomas.

Authors:  M Principi; M Italiani; A Guiducci; I Aprile; M Muti; G Giulianelli; P Ottaviano
Journal:  Neuroradiology       Date:  2003-03-05       Impact factor: 2.804

7.  Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.

Authors:  J Y Ljubimova; A J Lakhter; A Loksh; W H Yong; M S Riedinger; J H Miner; L M Sorokin; A V Ljubimov; K L Black
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

8.  Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.

Authors:  Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Rolf Buslei; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

9.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; T Hirai; T Okuda; Y Shigematsu; L Liang; Y Ge; Y Ushio; M Takahashi
Journal:  AJR Am J Roentgenol       Date:  1998-12       Impact factor: 3.959

10.  Myo-inositol: a marker of reactive astrogliosis in glial tumors?

Authors:  Elke Hattingen; Peter Raab; Kea Franz; Friedhelm E Zanella; Heinrich Lanfermann; Ulrich Pilatus
Journal:  NMR Biomed       Date:  2008-03       Impact factor: 4.044

View more
  17 in total

1.  Immediate post-operative MRI suggestive of the site and timing of glioblastoma recurrence after gross total resection: a retrospective longitudinal preliminary study.

Authors:  Thibault Smets; Tévi Morel Lawson; Cécile Grandin; Aleksandar Jankovski; Christian Raftopoulos
Journal:  Eur Radiol       Date:  2013-01-12       Impact factor: 5.315

2.  Comparison of 18F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study.

Authors:  Antoine Verger; Christian P Filss; Philipp Lohmann; Gabriele Stoffels; Michael Sabel; Hans J Wittsack; Elena Rota Kops; Norbert Galldiks; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-22       Impact factor: 9.236

3.  Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma.

Authors:  Roberto Sanz-Requena; Antonio J Revert-Ventura; Gracián García-Martí; Fares Salamé-Gamarra; Alexandre Pérez-Girbés; Enrique Mollá-Olmos; Luis Martí-Bonmatí
Journal:  Eur Radiol       Date:  2016-12-20       Impact factor: 5.315

4.  Pushing the limits of glioma resection using electrophysiologic brain mapping.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

5.  Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Authors:  Asim K Bag; Phillip C Cezayirli; Jake J Davenport; Santhosh Gaddikeri; Hassan M Fathallah-Shaykh; Alan Cantor; Xiaosi S Han; Louis B Nabors
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

6.  MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.

Authors:  Stella Blasel; Alina Jurcoane; Oliver Bähr; Lutz Weise; Patrick N Harter; Elke Hattingen
Journal:  J Neurooncol       Date:  2013-05-22       Impact factor: 4.130

Review 7.  Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?

Authors:  Natalie R Boonzaier; Sara G M Piccirillo; Colin Watts; Stephen J Price
Journal:  CNS Oncol       Date:  2015-10-26

8.  Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced MR in Tumor Parenchyma and Peritumoral Area for Distinction of Brain Tumors.

Authors:  Jing Zhao; Zhi-yun Yang; Bo-ning Luo; Jian-yong Yang; Jian-ping Chu
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

9.  Facing contrast-enhancing gliomas: perfusion MRI in grade III and grade IV gliomas according to tumor area.

Authors:  Anna Luisa Di Stefano; Niels Bergsland; Giulia Berzero; Lisa Farina; Elisa Rognone; Matteo Gastaldi; Domenico Aquino; Alessandro Frati; Francesco Tomasello; Mauro Ceroni; Enrico Marchioni; Stefano Bastianello
Journal:  Biomed Res Int       Date:  2014-04-03       Impact factor: 3.411

Review 10.  Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors.

Authors:  Lu Guo; Gang Wang; Yuanming Feng; Tonggang Yu; Yu Guo; Xu Bai; Zhaoxiang Ye
Journal:  Radiat Oncol       Date:  2016-09-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.